Infants and children (2 months to 10 years of age)
Very common (these may affect more than 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Your doctor, pharmacist or nurse may ask you to give your child medicines that help lower fever at the time, and after, BEXSERO has been administered. This will help reduce some of the side effects of BEXSERO.
Side effects that have been reported since the vaccine has been on the market include:
Allergic reactions may include severe swelling of the lips, mouth, throat (which may cause difficulty in swallowing), difficulty breathing with wheezing or coughing, rash, loss of consciousness and very low blood pressure; collapse (sudden onset of muscle floppiness), less responsive than usual or lack of awareness, and paleness or bluish skin discoloration in young children; feeling faint or fainting; fever (adolescents from 11 years of age and adults); injection site reactions like extensive swelling of the vaccinated limb, blisters at or around the injection site and hard lump at the injection site (which may persist for more than one month).
If any of the noted side effects become serious, or if you notice any side effects not listed here, please tell your doctor, pharmacist, or nurse immediately. This is not a complete list of side effects. For any unexpected effects while taking BEXSERO, contact your doctor, pharmacist, or nurse. If you need to report an adverse event, please call 1-800-387-7374.
Warnings and precautions
BEFORE your child receives BEXSERO, talk to your doctor, pharmacist, or nurse if:
Fainting, feeling faint or other stress-related reactions can occur as a response to any needle injection. Tell your doctor, pharmacist, or nurse if they have ever experienced this kind of reaction.
BEXSERO should not be used if your child is allergic (hypersensitive) to the active substances or any of the other components of the vaccine closure of BEXSERO. If your child has a weakened immune system, it is possible that the effectiveness of BEXSERO is reduced. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. Additionally, BEXSERO is not expected to protect against all circulating meningococcal serogroup B strains and doesn’t offer protection against strains A, C, Y and W-135. BEXSERO does not treat or reduce the consequences of meningococcal disease, including meningitis, sepsis, and death.
BEXSERO is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B bacteria in individuals from 2 months through 25 years of age.